PDF
Full
Outline
To compare the effects of different doses of budesonide and formoterol fumarate powder for inhalation combined with montelukast sodium tablet in the treatment of cough variant asthma (CVA) and the improvement of airway function and inflammatory factors.
Elderly patients with cough variant asthma were randomly divided into group A and group B. Both groups of patients received budesonide and formoterol fumarate powder for inhalation combined with montelukast sodium tablet. Group A was given budesonide and formoterol fumarate powder for inhalation(Ⅱ), 2 inhalation per time, twice a day; Group B was given budesonide and formoterol fumarate powder for inhalation, 4 inhalation per time, twice a day; budesonide fumatrol inhalation powder mist for continuous treatment for 6 months, and montelukast sodium tablet 10 mg once a day for at least 3 months. The nighttime cough scores of the two groups were compared before treatment and after treatment. The percentage of forced expiratory volume in one second (FEV1) in the predicted value, the maximum mid expiratory flow (MMEF), the fractional exhaled nitric oxide (FeNO), interleukin-5 (IL-5) and eosinophils were compared between the two groups. The incidence of adverse drug reactions and the recurrence rate within 1 year were compared between the two groups.
A total of 45 cases were enrolled in both the group A and the group B. At 9 months after treatment, the nocturnal cough scores of the group A and the group B were (0.93±0.42) and (0.65±0.29) points, respectively; the percentage of FEV1 in the predicted value were (97.75±9.67)% and (100.93±11.06)%, respectively; the MMEF values were (2.81±1.04) and (3.08±1.09) L·s-1, respectively; the FeNO values were (18.94±9.75) and (15.94±7.96) ppb, respectively; the IL-5 levels were (10.88±7.06) and (8.11±5.56) pg·mL-1, respectively. The above indicators in group B showed statistically significant differences compared to group A (all P<0.05). The total incidence of adverse drug reactions in group A and group B were 8.89% (5 cases/45 cases) and 13.33% (6 cases/45 cases), respectively. The recurrence rates was 15.56% (7 cases/45 cases) and 13.33% (6 cases/45 cases), respectively. There was no statistically significant difference in the above indicators between group B and group A (all P>0.05).
For elderly patients with CVA, higher dose of budesonide and formoterol fumarate powder for inhalation combined with montelukast sodium tablet can better improve cough symptoms, reduce the level of airway hyperresponsiveness and inflammatory factors, reduce the recurrence rate, and the patients are well tolerated.
PDF
0
0
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
